Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective multicenter cohort study of talimogene laherparepvec and immune checkpoint inhibitors on Increased risk of cutaneous immune-related adverse events

Next Previous
Trial Profile

A retrospective multicenter cohort study of talimogene laherparepvec and immune checkpoint inhibitors on Increased risk of cutaneous immune-related adverse events

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune checkpoint protein inhibitors (Primary) ; Talimogene laherparepvec (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions

Most Recent Events

  • 27 Mar 2023 New trial record
  • 19 Mar 2023 Results published in the Journal of the American Academy of Dermatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top